engleski

Sumamed® in the treatment of urogenital and sexually transmitted infections

Significant advancements in the treatment of urogenital (UGI) and sexually transmitted infections (STI) were achieved on a worldwide scale with the clinical use of Sumamed®. Sumamed® is effective against most common bacterial pathogens of urogenital and sexually transmitted infections, has anti-inflammatory and immunomodulatory effect, and is effective against bacterial biofilm. Sumamed® is administered once daily, it is well absorbed after oral use, rapidly distributed in the organism, achieves high concentrations, especially in infected tissues, builds up in lysosomes, is transmitted by phagocytes to the site of infection. It has a prolonged antimicrobial effect even several days after the last dose because of high and sustained concentrations in tissue and body fluids. Side effects are rare and mild. Sumamed® complies with the World Health Organization criteria for the treatment of sexually transmitted infections: 1) high efficiency (at least 95 % of microbiological efficacy) ; 2) low price ; 3) acceptable toxicity and tolerability ; 4) low possibility for inducing development of pathogen resistance to antimicrobials ; 5) simple for use ; 6) oral administration ; 7) possible use in pregnant women ; 8) efficiency in symptomatic and asymptomatic STI ; 9) its administration has a minimal effect on everyday life in patients ; 10) small possibility for accidental omission of a dose and 11) active against several different STI pathogens. Sumamed® in dose 1x1, 0 g orally is the drug of choice for the treatment of acute nongonococcal urethritis and mucopurulent cervicitis as well as for the treatment of chlamydial infections in pregnancy. In combination with metronidazole, in a total oral dose of 3, 0 g, it is recommended for the treatment of persistent urethritis. In a total dose of 3, 0 g orally, Sumamed® is used for the treatment of reactive arthritis induced by C.trachomatis and U.urealyticum infection, as a part of a combined treatment of pelvic inflammatory disease. Sumamed® is an effective and safe drug for the treatment of prostate infection caused by C.trachomatis and U.urealyticum, in a total dose of 4, 5 g orally for 3 weeks, administered for 3 days weekly in dose of 1x500 mg daily or in a total dose of 4, 0 g orally for 4 weeks administered as a single dose 1x1, 0 g orally per week. Conclusion: Sumamed® is effective against the most common causes of UGI and STI. It targets the site of infection ; it is safe for administration and simple for use. Taking into consideration years of personal clinical experience and active involvement in clinical studies, Sumamed® is the drug that justifiably deserves the confidence of physicians and patients.

*

nije evidentirano